Translational Development Acquisition (TDACW) Other Accumulated Expenses (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Other Accumulated Expenses for 3 consecutive years, with $166762.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses rose 256.62% year-over-year to $166762.0; the trailing twelve-month figure through Jun 2026 stood at $166762.0 (up 256.62% YoY), and the FY2025 full-year result was $106762.0, up 5238.1% from the prior year.
• Other Accumulated Expenses climbed to $166762.0 in Q2 2026 per TDACW's latest filing, from $136762.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $166762.0 in Q2 2026 and bottomed at $2000.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $79747.6 across 3 years, with a median of $76762.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses soared 5238.1% in 2025, then soared 256.62% in 2026.
• Over 3 years, Other Accumulated Expenses stood at $2000.0 in 2024, then jumped by 5238.1% to $106762.0 in 2025, then jumped by 56.2% to $166762.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $166762.0, $136762.0, and $106762.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.